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Knowledge of side effects associated with differ- 
ent cephalosporins may be of help to prescribers. 
There are several side effects that are common to 
all cephalosporins, but overall, cefotaxime and 
ceftizoxime cause the fewest adverse reactions. 
Bleeding is probably the most common serious 
side effect of cephalosporins. Moxalactam causes 
coagulopathy and bleeding more often than do 
other cephalosporins, probably because it is car- 
boxylated and has a methylthiotetrazole side 
chain. Cefoperazone also has a methyl- 
thiotetrazole side chain and may cause bleeding, 
particularly when used in doses greater than 4 g 
per day. Ceftriaxone has a similar side chain and 
there is some evidence that it can induce a coag- 
ulopathy. Coagulation tests should be monitored 
when any of the third-generation cephalosporins 
are given to patients with a high risk of bleeding. 
Disulfiram-like reactions are also related to the 
side chains associated with coagulation defects 
and have been reported when patients receiving 
cefoperazone, moxalactam, or ceftriaxone have 
ingested alcohol. Seizures have been reported 
with ceftazidime, but are uncommon. Hematolo- 
gic reactions are rare with all third-generation 
cephalosporins. Benign diarrhea and Clostridium 
difficile colitis probably occur most often with 
moxalactam, cefoperazone, ceftazidime, and cef- 
triaxone, but there are few good data on this 
issue. Ceftriaxone has the unique ability to cause 
sludge (also referred to as pseudolithiasis) to 
form in the gallbladder, particularly in children. 
This may be associated with nausea, anorexia, 
epigastric distress, and colic, and is usually de- 
tected using ultrasonography. The sludge dis- 
solves, and symptoms subside after therapy is dis- 
continued. None of the third-generation cephalo- 
sporins is clearly significantly nephrotoxic, even 
when combined with aminoglycosides. Most of 
the third-generation cephalosporins have surpris- 
ingly few serious side effects, which make them 
attractive for use in the treatment of a wide vari- 
ety of serious infections. 
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T hird-generation cephalosporins have a remarka- bly broad spectrum of antibacterial activity, and 
all of those currently available are administered via 
the parenteral route. They are, therefore, attractive 
for empiric therapy of serious or polymicrobial infec- 
tions. The six third-generation cephalosporins that 
will be discussed in this review are cefotaxi’me (Cla- 
foran), ceftizoxime (Cefizox), ceftriaxone (Roceph- 
in), moxalactam (Moxam, Latamoxef), cefoperazone 
(Cefobid), and ceftazidime (For&, Ceftaz, Tazicef). 
Extensive experience has showh that these agents are 
relatively free of serious side effects, which is remark- 
able in view of the confounding influence of the dis- 
ease-related adverse effects similar to those com- 
monly attributed to the use of these antimicrobials [l]. 
The overall rate of adverse effects is low and similar 
for all third-generation cephalosporins [1,2]? particu- 
larly when compared with the aminoglycosldes. The 
cephalosporins show slightly different side effect pro- 
files, some of which are related to differences in mo- 
lecular structure (e.g., coagulopathies resulting from 
the presence of the N-methylthiotetrazole [MTT] side 
chain). Other side effects are related to the broad- 
spectrum antibacterial activity of the cephalosporins 
or to their excretion in large amounts into the gastro- 
intestinal tract, with resultant marked changes in the 
microbial ecology of the bowel flora. Not surprisingly, 
there are some important differences between these 
antimicrobials in the frequency and nature of these 
adverse effects, and knowledge of these can be helpful 
to clinicians wishing to prevent or treat these compli- 
cations. 
All of the third-generation cephalosporins can cause 
local pain on administration, phlebitis, fever, pruritus, 
rashes, anorexia, nausea, vomiting, nonspecific diar- 
rhea, abnormal liver function tests, and positive direct 
Coomb’s antiglobulin tests on serum. These side ef- 
fects are usually mild and not serious, since they fre- 
quently subside promptly when the drug treatments 
are discontinued. All of these antimicrobials are capa- 
ble of causing serious allergic reactions, and should, 
therefore, be used with caution in patients who have 
previously had reactions to beta-lactam antimicrobi- 
als. 
COAGULATION DEFECTS AND BLEEDING 
Coagulopathies and bleeding are probably the most 
serious side effects caused by the third-generation 
cephalosporins. The most common mechanisms behind 
cephalosporin-induced coagulation deficits or bleeding 
are shown in Table I [3,4]. Most cases of bleeding as- 
sociated with these compounds are caused by either 
vitamin K-responsive hypoprothrombinemit, as mani- 
fested by prolongation of the prothrombin time, or an 
acquired platelet functional defect, as manifested by 
an increase in bleeding time. 
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TABLE I
Mechanisms of Cephalosporin-Induced Coagulation Deficits 
or Bleeding 
* Induction of vitamin K-responsive hypoprothrombinemia 
* Production of an acquired platelet defect 
* Thrombocytopenia secondary to bone marrow suppression 
* Immune thrombocytopenia 
* Inhibition of fibrin polymerization 
* Potentiation of the effects of coumadin 
TABLE II 
Number of Patients Reported to the United States Food and 
Drug Administratipn between 1981 and 1987 as Having 
Gastrointestinal Bleeding Resulting from Parenteral 












The relative frequency of coagulopathies and bleed- 
ing is not accurately documented for the different 
third-generation cephalosporins. An analysis of re- 
ports (as sent to the United States Food and Drug 
Administration between 1981 and 1987) is shown in 
Table II [4]. The numbers of patients treated with 
each agent were not reported. Approximately 25 per- 
cent of these patients who were reported to the Food 
and Drug Administration died, and though the cause 
of death was not necessarily bleeding, these data 
clearly indicate that coagulopathy and bleeding are 
serious complications of the use of cephalosporins. 
The lack of good comparative data is in part because 
in addition to the use of antimicrobials, these patients 
may also have important risk factors for bleeding, in- 
cluding malnutrition, poor dietary intake of vitamin 
K, use of nasogastrnz suction, gastrointestinal or he- 
patic disease, or renal disease, or they may undergo 
surgical procedures or prolonged intravenous therapy 
without vitamin K supplementation [51. 
Bleeding can occur with all the cephalosporins, but 
it appears that coagulopathies and bleeding are most 
frequent when the cephalosporin molecule contains a 
M’IT side chain [6]. For third-generation cephalospo- 
rins, this moiety is found in both moxalactam [7-91 
and cefoperazone [lO,ll]. Ceftriaxone contains a re- 
lated structure, N-methylthiotriazone (MTZ) (Figure 
l), the significance of which, with respect to coagula- 
tion defects, remains controversial. Nonetheless, 
more cases of bleeding, particularly from the gastroin- 
testinal tract, have been reported in association with 
moxalactam than with any other widely used cephalo- 
sporin for which good data are available [4]. This prob- 
ably results from adverse effects on both prothrombin 
synthesis and platelet function, as discussed in the fol- 
lowing sections. 
ANTlBIOTIC-INDUCED HYPOPROTHROMBINEMIA 
Vitamin K is a cofactor in the hepatic microsomal 
carboxylation of the precursors of prothrombin (clot- 
ting factor II) known as convertin (factor VII), antihe- 
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Ffgure 1. Structures of various third-generation cephalosporins. Note the presence 
of the MTT side chain on both the cefoperazone and moxalactam molecules. These 
are associated with bleeding from the gastrointestinal tract. The role of the related 
MT?! group on the ceftriaxone molecule with respect to coagulation defects is 
unknown, The alpha-carboxyl group on moxalactam is associated with a functional 
defect in platelets; the oxygen in the secondary ring structure probably facilitates 
splitting of the MlT side chain, thus permitting its enterohepatic recirculation. 
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TABLE Ill 
Characteristics of Immune Hematologic Adverse Reactions 
following Administration of Third-Generation Cephalosporins 
9 Relatively uncommon 
@ Produces a positive Coomb’s antiglobulin test (3 percent of patients!) 
* Hemolytic anemia known to be caused by ceftriaxone 
* Leukopenra is induced by high-dose therapy for 2-3 weeks with cephalosporins. This is 
rapidly reversible 
l Thrombocytopenia IS rare, but can occur with ceftnaxone and cefotaxime 
mophilic factor B (factor IX), and Stuart-Prower fac- 
tor (factor X). These clotting factors must undergo 
carboxylation in order to bind to phospholipid surfaces 
and to contribute to the formation of a fibrin clot at a 
bleeding point [12]. During carboxylation, vitamin K 
is inactivated and must be replaced or reactivated to 
allow -continued conversion of precursors to the car- 
boxylated form. Vitamin K1 (phylloquinine) is the pri- 
mary source of vitamin K for humans, and is derived 
from dietary sources, whereas vitamin Kz (meno- 
quinone) is produced by micro-organisms within the 
lumen of the colon. Such microbial vitamin K2 be- 
comes a highly important source of vitamin K when 
dietary sources are deficient. Malnourished, vitamin 
K-deficient patients receiving parenteral feeding 
without vitamin K supplementation are highly depen- 
dent on these endogenous sources, and are, therefore, 
susceptible to bleeding, owing to antibiotic-induced 
reductions in the numbers of coliforms and Bacte- 
roides in the colon. Both of these groups of organisms 
are of major importance in the synthesis of vitamin Kz 
[13]. It is possible, therefore, for cephalosporin antibi- 
otics to interfere with the generation of clotting fac- 
tors in two ways: (1) by affecting intestinal synthesis 
of vitamin Ks; and (2) by impairing the carboxylation 
of vitamin K in the liver. In vitamin K-deficient pa- 
tients, a prolonged prothrombin time may be ob- 
served within a few days of starting antibiotics. This 
abnormality is, however, readily reversed by the par- 
enteral administration of 5 to 10 mg of vitamin K, un- 
less liver function is impaired. Thus, patients who are 
already deficient in vitamin K are at increased risk of 
bleeding, particularly if receiving MTT- or MTZ- 
containing antibiotics, which may further impair vita- 
min K metabolism. 
Cefoperazone and ceftriaxone are excreted in large 
amounts via the biliary tract (in contrast to cefotax- 
ime, ceftizoxime, and ceftazidime, which are elimi- 
nated primarily via the kidneys) and can produce both 
marked changes in the fecal flora and marked reduc- 
tions in vitamin Kz. The MTT side chain found on mox- 
ala&am and cefoperazone and the MTZ moiety found 
on ceftriaxone (Figure 1) can also inhibit the hepatic 
microsomal carboxylases that aid in the generation of 
catalytically active vitamin K [7,14]. 
The MTT side chain of moxalactam is readily hydro- 
lyzed, owing to the oxygen molecule in its secondary 
ring (Figure l), which eventually results in the enter- 
ohepatic cycling of high concentrations of this entity. 
Therefore, patients at risk of bleeding must be rec- 
ognized? monitored, and given vitamin K either pro- 
phylactically or therapeutically (if bleeding has al- 
ready occurred). Administration of fresh frozen 
plasma may also be used to restore clotting factors to 
normal, subsequent to the onset of bleeding. 
SYMPOSIUM ON THIRD-GENERATION CEPHALOSPORINS I FEKETY 
Platelet Dysfunction Induced by Antibiotics 
Some beta-la&am antibiotics irreversibly inhibit 
adenosine diphosphate-dependent platelet aggrega- 
tion, a process that normally plays a key role in he- 
mostasis [14]. This phenomenon is recognized by a 
prolongation of the bleeding time. 
Both carbenicillin and moxalactam have been shown 
to markedly prolong the bleeding time of volunteers 
[15], a property that has been related to the alpha- 
carboxyl side chain (Figure l), which also enhances 
their anti-pseudomonal activity. There is a delay of 
two or three days after administration of moxalactam 
before the increased bleeding time becomes evident. 
Prolonged bleeding may be detected or monitored 
irz vitro by the technique known as platelet ag- 
gregometry, performed in the presence of adenosine 
diphosphate [7,161, and has been found to depend on 
both the concentration of the antibiotic and the dura- 
tion of treatment. Alpha-carboxylated beta-lactams, 
such as carbenicillin, ticarcillin, and moxalactam, have 
the greatest inhibitory effect on platelet aggregation. 
Other cephalosporins lack this side chain and have 
only slight effects on platelet function. Moxalactam 
(greater than 4 g per day for one week) consistently 
impairs platelet function and prolongs the bleeding 
time, whereas ceftriaxone and ceftizoxime (6 g per 
day) have no demonstrable effect on platelet function 
DV. 
In the presence of renal or hepatic dysfunction, 
many other antimicrobials may predispose to bleeding 
by this or related mechanisms. The “template bleed- 
ing time” technique appears to be the best way to 
monitor the bleeding tendency secondary to platelet 
dysfunction [181. Treatment of the defect and of the 
bleeding it causes requires transfusion of fresh plate- 
lets and discontinuation of the causative agents; vita- 
min K administration does not appear to be helpful. 
HYPERSENSITIVITY REACTIONS 
The third-generation cephalosporins share major 
and minor antigenic determinants with penicillins. In 
vitro these compounds often cross-react with antibod- 
ies to various other penicillins or cephalosporins, but 
such antibody reactions do not appear to be useful as 
predictors of clinical allergic reactions [191. 
Serious allergic reactions during treatment with 
cephalosporins are uncommon. Nonetheless, anyone 
with a history of penicillin allergy may develop a simi- 
lar allergic reaction when given a cephalosporin, but a 
history of delayed allergic reactions to penicillins is 
only a relative contraindication to cautious adminis- 
tration of a third-generation cephalosporin. However, 
if immediate reactions (urticaria or anaphylaxis) to 
penicillins have occurred, it is prudent to avoid the use 
of any cephalosporin. Desensitization has been tried 
with success in a few such patients, but is not entirely 
reliable. 
IMMUNE MEDIATED HEMATOLOGIC REACTIONS 
All of the cephalosporins may cause immune hema- 
tologic reactions (Table III). Immune hemolytic ane- 
mia or thrombocytopenia may be caused when the 
cephalosporin acts as a hapten, which reacts with cel- 
lular proteins to form antigens that elicit antibody re- 
actions. Such reactions may result from the participa- 
tion of the antigen in formation of immune complexes 
that become attached in a nonspecific way to platelets, 
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from the reaction of the antibody with cell-bound 
drug, from the induction of antibodies directed only 
against intrinsic cellular antigens, or from a combina- 
tion of these mechanisms. 
In the third-generation class, hemolytic anemias 
have been described only with ceftriaxone, although 
positive direct Coomb’s antiglobulin tests can be seen 
in about 3 percent of patients receiving cephalosporins 
r201. 
Leukopenia secondary to reversible suppression of 
the bone marrow has been reported after two to three 
weeks of high-dose therapy with cephalosporins. 
Characteristic features include depletion of bone mar- 
row precursors, marrow cell proliferation, and im- 
mune-mediated destruction of granulocytes. If leuko- 
penia becomes a problem, the blood count may be 
monitored, with discontinuation of the antibiotic ther- 
apy if the condition becomes severe; recovery is usu- 
ally prompt. 
Immune-mediated thrombocytopenia is rare with 
these antimicrobials, but has been reported with both 
ceftriaxone and cefotaxime [20,21]. In one study it 
was observed in 3.3 percent of recipients of cefotax- 
ime, and a similar rate was observed in recipients of 
cefazolin 1211. Moxalactam, which has an oxygen atom 
rather than a sulfur in the secondary ring structure 
(Figure l), is less likely to cross-react with the penicil- 
lin antibodies since it does not readily form sulfhydryl 
bonds. Thus, moxalactam is useful in cases in which a 
cephalosporm is required but in which there is a previ- 
ous history of immune reactions to penicillin or other 
cephalosporins. 
Some of the cephalosporins can adversely affect pol- 
ymorphonuclear chemotaxis (cefoperazone), or sup- 
press lymphocyte mitogenic responses (ceftriaxone), 
but the clinical significance of these observations is 
unknown [22]. 
GASTROINTESTINAL SIDE EFFECTS 
Symptoms of the gastrointestinal side effects of 
third-generation cephalosporins are protean, and in- 
clude nausea, vomiting, anorexia, abdominal cramps, 
and diarrhea. The characteristics of these side effects 
are shown in Table IV. They are usually benign or 
self-limited, and resolve rapidly after the drug treat- 
ments are discontinued. Many of these symptoms are 
often attributed, without much supporting evidence, 
to direct irritation of the intestinal mucosa by the anti- 
microbial. If so, they might be more frequent with 
moxalactam, cefoperazone, and ceftriaxone, the ana- 
logues of which are excreted to the greatest extent via 
the biliary tract, though no good clinical data exist to 
support this theory. It has been postulated that cefo- 
perazone increases secretion of bile salts into the in- 
testines, and that the resultant high concentration of 
bile salts causes diarrhea (Jacobson CE, personal com- 
munication). In addition, studies suggest that cefope- 
razone and ceftriaxone produce the most marked 
changes and cefotaxime the least, in the normal fecal 
flora, with selection of resistant pathogens. These 
changes are probably responsible for many of the ad- 
verse effects such as super-infection, diarrhea, and co- 
litis [23-251. 
In addition to impairing synthesis of vitamin KZ in 
the colon, these changes in fecal flora favor intestinal 
superinfection or overgrowth with Enterococcus fae- 
calis, Clostridium difficile (see the following section), 
TABLE IV 
Characteristics of Gastrointestinal Side Effects of the Third- 
Generation Cephalosporins 
* Nonspecific diarrhea (dysbiosis), particularly with moxalactam, cefoperazone, and 
ceftriaxone 
0 Increased bile salt excretion with cefooerazone 
* All third.generation cephalosporins can cause CMidium d/fRci/e colitis 
(pseudomembranous colitis). Pseudo-epidemics may occur. Colitis sometimes begins 
after therapy is dscontinued 
* Overgrowth of resistant organisms 
* Interference with vitamin K synthesis 
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and Candida. Resistant organisms in the intestines 
appear capable of transmitting genetic factors respon- 
sible for antimicrobial resistance via plasmids, so they 
are likely to be epidemiologically important in produc- 
tion of nosocomial infections caused by antibiotic- 
resistant organisms. 
Pseudomembranous Colitis Caused by C. di#kIe 
Toxigenic C. difficile can be found in the feces of 
more than 10 to 20 percent of hospitalized adults 
treated with antibiotics. Overgrowth of this organism 
may result in production of large amounts of its tox- 
ins, which have been implicated in the origin not only 
of diarrhea and pseudomembranous colitis, but also of 
toxic megacolon, severe diarrhea in Hirschsprung’s 
disease, and worsening or relapse of diarrhea in pa- 
tients with chronic inflammatory bowel diseases. 
All the third-generation cephalosporins have been 
implicated in cases of C. difficile-induced pseudomem- 
branous colitis, and the rates of this complication are 
not clearly higher for those antimicrobials excreted 
primarily via the biliary tract and found in high con- 
centrations in feces. In premarketing trials, diarrhea 
of unspecified cause was arguably more common with 
cefoperazone (3.3 percent of treated patients) than 
with moxalactam (2.5 percent), ceftizoxime (1.8 per- 
cent), or cefotaxime (1.2 percent) [26]. This apparent 
paradox may be explained by the fact that even low 
fecal concentrations of antimicrobials (such as those 
reached when parenteral cephalosporins excreted pri- 
marily by the kidneys are also excreted to a lesser 
extent via the biliary route) are adequate to disturb 
the delicate balance in the fecal flora. In fact, antimi- 
crobials like cefoperazone, which is found in high con- 
centrations in feces, may inhibit growth of seemingly 
resistant C. difficile isolates in the intestinal tract 
until after the antibiotic therapy is discontinued, when 
the organism has an opportunity to multiply and cause 
disease. Such a delay in onset of the colitis makes it 
particularly difficult for clinicians to associate it with 
the inducing antibiotic. 
Perhaps the most important point to remember 
about pseudomembranous colitis is that it may be 
seen, albeit only occasionally, with use of any of the 
third-generation cephalosporms. 
HEPATIC AND BILIARY SYSTEMS 
Mild, reversible abnormalities in liver function tests 
are not uncommon in patients receiving third-genera- 
tion cephalosporins, but there have not been any re- 
ports of clinically evident toxicity or hypersensitivity. 
Ceftriaxone has the unique property of causing 
sludge (pseudolithiasis) to form in the gallbladder, 
particularly in children 12’7,281. None of the other 
April 9, 1990 The American Journal of Medicine Volume 88 (suppl 4A) 4A-41s 
TABLE V 
Superinfecting Organisms Commonly Found after Treatment 
with Third-Generation Cephalosporins 
Gram-positive organisms 
@ Staphylococcusaureus(particularly with cefoperazone but also with ceftazidime, 
moxalactam, and more seldom with cefotaxime) 
* fnterococcus hecais (particularly with moxalactam, ceftazidime, and ceftriaxone but 
can occur with all third-generation cephalosporins) 
Gram-negative organisms 
@ Pseudomonas aerugima (cefoperazone, ceftriaxone and moxalactam permit much 
more overgrowth than do eefotaxime, ceftizoxime, and ceftazidime) 
Fungi 
@ Candida (as for t? aenlginosa, see above] 
cephalosporins has been reported to cause this syn- 
drome. Associated symptoms may include nausea, 
epigastric distress, colic, and tenderness to palpation 
or fist percussion in the right upper quadrant; the clin- 
ical picture resembles acute cholecystitis. The sludge 
is of uncertain composition, mobile, and best detected 
using ultrasonography. In a prospective ultrasonogra- 
phy study [27], 43 percent of 37 treated patients 
showed biliary “concrements” and one patient (3 per- 
cent) had urolithiasis. Three of 16 with gall bladder 
concrements also had biliary symptoms., which re- 
solved within five days after discontinuation of ceftri- 
axone. The authors speculated that the abnormality 
was seen most commonly when ceftriaxone was given 
by intravenous bolus over three to five minutes. Cho- 
lecystectomy has been carried out on patients who 
have developed this syndrome, but there is increasing 
awareness of the syndrome and with it recognition 
that symptoms subside and the sludge gradually dis- 
solves after the drug treatment is discontinued. Cho- 
lecystectomy is probably best avoided in these pa- 
tients, but the drug treatment should be discontinued 
when these symptoms appear. Although this is a rela- 
tively benign side effect, it can be a disturbing one. 
A high proportion (more than 90 percent) of circu- 
lating ceftriaxone is bound to serum proteins and con- 
sequently may displace bilirubin from protein binding 
sites, thus causing a slight hyperbilirubinemia [29,30]. 
As a result, there may be an increased frequency of 
the complications of hyperbilirubinemia in neonates 
(particularly those already hyperbilirubinemic) 
treated with ceftriaxone. Ceftriaxone should be 
avoided in all such cases. 
At present, there is insufficient knowledge of the 
problems of biliary sludge and hyperbilirubinemia. It 
is not known whether the hyperbilirubinemia is re- 
lated in any way to the mechanism of formation of gall- 
bladder sludge! but it is apparent that ceftriaxone has 
some unique side effects relative to the biliary tract 
that are worthy of further investigation. 
SUPERINFECTIONS 
The broad spectrum of antibacterial activity of the 
third-generation cephalosporins can result in profound 
changes in the normal flora at various sites in the 
body, particularly the gastrointestinal tract, vagina, 
skin, and upper respiratory tract. If resistant organ- 
isms increase greatly in numbers at those sites, an 
increase in both mucocutaneous or systemic infections 
by opportunistic organisms may be the result. The 
acquisition of antibiotic-resistant pathogens from ex- 
ogenous nosocomial sources may also be facilitated by 
use of these antibiotics. Although colonization is more 
frequent than infection with such organisms, it is 
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often difficult to distinguish between colonization and 
superinfection, and unnecessary and expensive 
changes in antibiotic therapy may then result. 
The third-generation cephalosporins were designed 
primarily to have good activity against gram-negative 
bacilli, but this was accompanied by a lesser degree of 
activity against staphylococci and enterococci. This 
differential antibacterial activity is particularly evi- 
dent with ceftazidime, moxalactam, and cefoperazone, 
which are much less active than cephalothin or cefazo- 
lin against these staphylococci and enterococci. In 
vitro, cefotaxime has the best antistaphylococcal ac- 
tivity of all third-generation cephalosporins (Fekety 
and Cimino, unpublished observations) [31]. Ceftriax- 
one has almost equivalent activity! except in the pres- 
ence of serum (as a result of the high affinity of ceftri- 
axone for serum proteins). These findings may be of 
importance for treatment of neutropenic patients with 
staphylococcal infections, in whom good antibacterial 
activity may play a decisive role. None of the cephalo- 
sporins is active against methicillin-resistant staphy- 
lococci, and if used in treatment of these infections, 
there is a high clinical failme rate. 
The reported incidence of superinfections during 
therapy with parenteral cephalosporins ranges from 1 
to 15 percent [32]. These are caused most often by 
enterococci, very resistant gram-negative bacilli such 
as Pseudomonas, and fungi such as Candida (Table 
V). Those antibiotics with the least biliary excretion 
(cefotaxime, ceftizoxime, and ceftazidime) appear to 
result in less overgrowth by resistant organisms in 
stools than do those agents, such as cefoperazone, cef- 
triaxone, and moxalactam, that are excreted in bile in 
large amounts. 
Resistance of gram-negative bacilli to the third- 
generation cephalosporins may be mediated by induci- 
ble (chromosomal) beta-lactamases. These can become 
stably depressed, and resistance may continue after 
the inducing drug treatment has been discontinued. 
Pathogens most likely to have this ability include 
Pseudomonas aeruginosa, Enterobacter cloacae, 
Citrobacter, Serratia, Proteus spp., Prowidencia, and 
Acinetobacter. 
Enterococcal superinfections have been reported 
most often in patients receiving moxalactam (2 to 8 
percent of cases), but they have also been reported 
less commonly in patients treated with ceftizoxime, 
ceftazidime, and cefotaxime 132,331, with the lowest 
incidence reported for cefotaxime [34]. 
NEPHROTOXICITY 
Cephalosporins have the capacity for causing renal 
injury as a result of hypersensitivity-induced intersti- 
tial nephritis, by direct toxicity to the renal tubules, 
or by synergistic action with other nephrotoxic com- 
pounds, such as aminoglycoside antibiotics or loop diu- 
retics. In theory, any cephalosporin can induce inter- 
stitial nephritis, but significant nephrotoxicity has not 
yet been reported with any of the third-generation 
cephalosporins. In addition, there is no convincing evi- 
dence that any third-generation cephalosporins poten- 
tiate the nephrotoxicity of aminoglycosides or loop 
diuretics. There are a few reported cases of mild renal 
impairment occurring following use of ceftriaxone and 
ceftazidime, and one of the reports urged caution in 
the use of ceftazidime in patients with impaired renal 
function or in combination with aminoglycosides 
133,351. However, there is no good evidence that any 
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cephalosporin other than cephaloridine (which is no 
longer available in the United States) is nephrotoxic. 
In rabbits, extremely large doses of either moxalac- 
tam or cefotaxime caused no detectable renal abnor- 
malities, and in rats, ceftazidime actually reduced the 
nephrotoxicity of gentamicin [36]. 
There is no good clinical evidence for or against a 
synergistic toxicity of the third-generation cephalo- 
sporins with other nephrotoxins, such as aminoglyco- 
sides. Overall, it appears that these cephalosporins 
have a low nephrotoxic potential, in marked contrast 
to the aminoglycosides [37]. This is a major argument 
for the use of third-generation cephalosporins rather 
than aminoglycosides in many patients with serious 
infections. 
NEUROTOXICITY 
Headaches, paresthesias, and other mild central 
nervous system side effects have been reported with 
all third-generation cephalosporins. Seizures have 
been reported in patients treated with ceftazidime, 
but not with cefotaxime, ceftizoxime, or ceftriaxone 
[38]. All the third-generation cephalosporins other 
than cefoperazone show marked penetration across 
the blood brain barrier, particularly in cases of menin- 
geal inflammation. Thus it is possible that most cepha- 
losporins have the capacity to occasionally cause sei- 
zures, if given in doses sufficient to produce high con- 
centrations in serum and brain. 
DISULFIRAM-LIKE REACTIONS 
l%sulfiram-like (Antabuse) reactions consist of a 
variety of symptoms, as shown in Table VI. They 
occur in patients taking disulfiram who ingest alco- 
holic beverages. These reactions can also be produced 
by consuming ethanol while receiving certain cephalo- 
sporins, notably those containing the MTT side chain 
at the 3-position of the nucleus (Figure 1). The MTT 
side chain has structural similarity to disuliiram and it 
is thought to cause these reactions by a similar mecha- 
nism, namely by binding to and interfering with the 
action of the liver enzyme aldehyde dehydrogenase, 
which metabolizes the acetaldehyde breakdown prod- 
uct of ethanol to water and carbon dioxide. Accumula- 
tion of acetaldehyde is thought to cause the symp- 
toms. There is a notable time lag between administra- 
tion of the cephalosporin and susceptibility to the re- 
action after subsequent ingestion of ethanol. This is 
consistent with the notion that a metabolite of the an- 
tibiotic is important in causing the reaction. It has also 
been suggested that the time required for release of 
the free M’IT side chain or its attachment to the en- 
zyme may account for the lag period [39]. Medications, 
such as elixirs and cough syrups containing alcohol, 
have been implicated in some cases of disulfiram-like 
reactions. 
Moxalactam and cefoperazone are the analogues 
most likely to cause these reactions. There is one re- 
port of a disulfiram-like reaction in a patient given cef- 
triaxone. In this case, it is possible that the MTZ 
group of the ceftriaxone molecule was metabolized to 
a compound resembling the moxalactam or cefopera- 
zone MTT group metabolite [401. 
COMMENTS 
Third-generation cephalosporins are remarkably 
safe antimicrobials, particularly when compared with 
the aminoglycosides. However, they can occasionally 
TABLE VI 
Characteristics of Third-Generation Cephalosporin-Induced 
Disulfiram-Like (Antabuse) Reactions with Ethanol 
l Related to the Mll side chain of moxalactam and cefoperazone 
* One case has been demonstrated with ceftnaxone (Ml2 sidechain) 






Nausea and vomiting 
I Confusion Warmth, sweating and flushing 
Tachycardia - 
Hypotension 
e Delayed onset of symptoms after ingestion of antibiotic 
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produce serious reactions. Bleeding, superinfections, 
disulfiram-like reactions, and pseudomembranous co- 
litis are the most important complications. Although 
the rate of adverse reactions does- not vary greatly 
among the third-generation agents, cefotaxime and 
ceftizoxime appear to be associated with the lowest 
frequency of serious side effects, and moxalactam is 
associated with the highest frequency, primarily as a 
result of a unique propensity to cause coagulopathies 
and bleeding. Considering their broad antibacterial 
spectrum and low frequency of adverse reactions, the 
third-generation cephalosporins are useful alone or in 
combination with other antimicrobials for treatment 
of serious infections in hospitalized patients. 
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